BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Appoints John Landry as Chief Financial Officer

CVRx (CVRX)CVRxCommercial

Landry Brings Two Decades of Medtech and Public Company Finance Experience MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for

Related news

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

RYTMRhythm Pharmaceuticals2026-08-17 12:00 EST

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

HYPRHyperfine2026-08-26 12:15 EST

Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

STIMNeuronetics2026-07-20 20:05 EST

Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

ICCMIceCure Medical2026-08-12 12:30 EST

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-08-11 11:00 EST

CVRx Announces Sales Leadership Transition

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

Stock data

Close
3.04 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States